Skip to main content

CSL Named Fastest Growing Brand in Biopharma Industry

Brand Finance survey results follow CSL’s FY23 rebranding campaign, completion of its CSL Vifor acquisition, increased CSL Plasma collections, and the launch of CSL Behring’s first gene therapy.

We Are CSL featuring business units CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor

CSL’s brand value has jumped more than 30% over the past year to make it the fastest growing brand in the biopharmaceutical industry, according to a new report from consultant Brand Finance.

The report lists CSL’s brand value at USD $1.3 billion, which is up 80% since 2020. The company’s recent rebranding and moves – including the acquisition of CSL Vifor, increased collection volumes from CSL Plasma and the launch of CSL Behring’s first gene therapy – “position the brand to continue its impressive growth trajectory,” according to Brand Finance.

The results follow the August 2022 launch of CSL’s unified global brand identity, which incorporated a paid media campaign to define CSL’s brand for the industry and beyond. It also follows the launch of CSL’s first-ever brand anthem film, PROMISES, which debuted earlier in 2022.

“Recognition as our industry’s fastest-growing brand is the result of our focused global brand strategy and exemplary execution across the CSL enterprise as well as a multi-year effort to elevate our company’s external profile,” said CSL’s Chief Communications & Brand Officer Anthony Farina. “We look forward to continuing to grow the CSL brand by amplifying the unique story of our promise with stakeholders around the world.”

The Brand Finance report is an independent analysis developed from publicly available information. It defines brand value as “the present value of earnings specifically related to brand reputation.”

Last month, CSL was named among the top 500 companies in the Forbes 2000, a list that ranks companies based on sales, profits, assets and market value. Traded on the Australian Securities Exchange, CSL is a global biotech company that has 32,000 employees and provides medicines to 100 countries.

CSL includes business units CSL Behring, which makes medicines for people who have rare and serious diseases; CSL Seqirus, which develops and manufactures vaccines; and the recently acquired CSL Vifor, a leader in iron deficiency and nephrology (kidney care).

CSL also operates CSL Plasma, one of the largest collectors of donated human plasma used to make medicines for diseases such as hemophilia and primary immune deficiency.

For more on CSL’s brand, please visit